With much of Moderna’s recent rise tied to its COVID-19 vaccine, the company has struggled to match the sales highs it ...

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash following a series of setbacks for the biotech.

At an analyst day event, Moderna said it wants to invest revenue from a hopefully expanded seasonal vaccine franchise into oncology and rare disease programs, to “set the stage for additional growth ...

US biotech Moderna has held an analyst day event providing updates on its mRNA pipeline progress and a three-year plan for ...

Moderna (MRNA) shares have been under pressure lately, slipping around 8% over the past month. Investors continue to weigh up ...

Ahead of its Analyst Day event on Thursday, Moderna (MRNA) indicated ~10% revenue growth for next year and increased its ...

Shares of Moderna are falling Thursday. The company made two significant announcements regarding its finances and business ...

Moderna has secured a major financing deal as it works toward a 2028 cash breakeven goal that some analysts are questioning. The Cambridge drugmaker is shifting its focus to seasonal vaccines while ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we are going to look at where Moderna, Inc. (NASDAQ:MRNA) stands against other ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Moderna Inc.’s stock reached a 52-week low, closing at 23.04 USD, reflecting a significant downturn over the past year. The biotech company’s shares have experienced a substantial decline, with a year ...

The Department of Health and Human Services (HHS) has axed a $590 million contract with Moderna, raising doubts about how the biotech will fund late-phase development of a pandemic bird flu vaccine.